Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Common Equity (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Common Equity for 16 consecutive years, with $50.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity rose 10.19% to $50.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $50.4 million, a 10.19% increase, with the full-year FY2024 number at $43.0 million, down 16.33% from a year prior.
  • Common Equity was $50.4 million for Q3 2025 at Xtant Medical Holdings, up from $48.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $54.7 million in Q3 2023 to a low of $28.1 million in Q2 2022.
  • A 5-year average of $39.4 million and a median of $34.2 million in 2022 define the central range for Common Equity.
  • Biggest YoY gain for Common Equity was 172.31% in 2021; the steepest drop was 31.98% in 2021.
  • Xtant Medical Holdings' Common Equity stood at $30.9 million in 2021, then increased by 10.65% to $34.2 million in 2022, then soared by 50.27% to $51.3 million in 2023, then dropped by 16.33% to $43.0 million in 2024, then increased by 17.27% to $50.4 million in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Common Equity are $50.4 million (Q3 2025), $48.5 million (Q2 2025), and $43.9 million (Q1 2025).